- Home
- LXRX vs ASPI Comparison
LXRX vs ASPI Comparison
Compare LXRX & ASPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXRX | ASPI |
|---|---|---|
| Founded | 1995 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 660.9M | 637.1M |
| IPO Year | 2000 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LXRX | ASPI |
|---|---|---|
| Price | $1.68 | $5.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.15 | ★ $12.00 |
| AVG Volume (30 Days) | 2.1M | ★ 4.2M |
| Earning Date | 05-12-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,803,000.00 | $23,849,000.00 |
| Revenue This Year | N/A | $68.41 |
| Revenue Next Year | N/A | $126.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 60.24 | ★ 475.48 |
| 52 Week Low | $0.51 | $3.92 |
| 52 Week High | $1.95 | $14.49 |
Technical Indicators
Market Signals| Indicator | LXRX | ASPI |
|---|---|---|
| Relative Strength Index (RSI) | 47.92 | 55.71 |
| Support Level | $1.47 | $5.18 |
| Resistance Level | $1.81 | $5.90 |
| Average True Range (ATR) | 0.10 | 0.47 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 31.25 | 76.32 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.